- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04739774
Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)
Open-label, Non-randomized, One Sequence Cross-over Study to Investigate the Effect of Inhibition of CYP3A4/5 by Itraconazole on the Pharmacokinetics of CHF6001 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is a single centre, single dose Phase I study, with a non-randomized, open label, one sequence cross-over design.
A total of 24 healthy male and female are planned to be included.
Participants will be dosed with CHF6001 before and during co-administration of Itraconazole and will act as their own control. The study will be run with a one-sequence crossover design, where all subjects will be treated with CHF6001 in the first treatment period and CHF6001+Itraconazole in the second treatment period in order to avoid the need of a very long washout from the CYP3A4/5 inhibitor.
Standard safety assessments will be conducted during the Study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs and observations of any adverse events. Blood samples will be also collected for PK analysis.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Life Sciences - Clinical Pharmacology Unit Antwerpen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's written informed consent obtained prior to any study-related procedure;
- Healthy male and female subjects aged 18-55 years inclusive;
- Ability to understand the study procedures, the risks involved and ability to be trained to use the inhalers correctly and to generate sufficient PIF using the In-Check device.
- Body Mass Index (BMI) between 18,0 and 35,0 kg/m2 extremes inclusive;
- Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year prior to screening;
- Good physical and mental status
- Vital signs within normal limits
- 12 -lead digitalized Electrocardiogram (12-lead ECG) considered as normal
- Pulmonary function test within normal limits
- Women of Childbearing Potential (WOCBP) with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method in addition to a barrier contraception method from the signature of the informed consent and until the follow-up visit. Males with non-pregnant WOCBP partners: they and or/ their partner must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until the follow-up visit
Exclusion Criteria:
- Participation to another clinical trial where investigational drug was received, and last investigations were performed less than 8 weeks prior to screening;
- Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders, gastric surgery recent or in the past, and/or impaired gastric motility
- Clinically relevant abnormal laboratory values
- Abnormal liver enzymes at screening
- Subjects with history of breathing problems
- Positive HIV1 or HIV2 serology
- Positive results from the Hepatitis serology
- Blood donation or blood loss (equal or more than 450 ml) less than 2 months prior to screening or before the first dosing;
- Positive urine test for cotinine
- Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test
- Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen
- Intake of non-permitted concomitant medications in the predefined period
- Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before the first dosing;
- Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
- Known allergy to antifungal medicines;
- Unsuitable veins for repeated venipuncture;
- Heavy caffeine drinker
- For females only: pregnant or lactating women. Serum pregnancy test to be performed at screening and urine pregnancy test to be performed before the first dosing;
- Subjects receiving treatment with any drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole) within the previous 3 months before the screening visit
- Subjects using e-cigarettes within 6 months before screening.
- Positive documented COVID-19 test before admission
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment R
Single dose of CHF6001
|
Single dose of CHF6001
|
Experimental: Treatment T
Single dose of CHF6001 administered after repeated doses of oral Itraconazole
|
Single dose of CHF6001
Repeated doses of oral Itraconazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter (Cmax)
Time Frame: Over 96 hours after administration in blood
|
Peak Plasma Concentration (Cmax) for CHF6001
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (AUCt)
Time Frame: Over 96 hours after administration in blood
|
Area under the plasma concentration versus time curve (AUCt) for CHF6001
|
Over 96 hours after administration in blood
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter (AUC0-96)
Time Frame: Over 96 hours after administration in blood
|
Area under plasma concentration from 0 to 96 hours (AUC0-96) for CHF6001, CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (AUC0-∞)
Time Frame: Over 96 hours after administration in blood
|
Area under curve extrapolated to infinity (AUC0-∞) for CHF6001, CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (tmax)
Time Frame: Over 96 hours after administration in blood
|
Time of the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (t1/2)
Time Frame: Over 96 hours after administration in blood
|
Terminal half-life (t1/2) for CHF6001, CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (CL/F)
Time Frame: Over 96 hours after administration in blood
|
Apparent systemic clearance (CL/F) for CHF6001
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (AUCt)
Time Frame: Over 96 hours after administration in blood
|
Area under the plasma concentration versus time curve (AUCt) for CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Pharmacokinetic parameter (Cmax)
Time Frame: Over 96 hours after administration in blood
|
Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095
|
Over 96 hours after administration in blood
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
- CLI-06001AA1-11
- 2020-003769-21 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
-
Poitiers University HospitalCompletedBroncho Chronic Obstructive Pulmonary DiseaseFrance
Clinical Trials on CHF6001 DPI
-
Chiesi Farmaceutici S.p.A.CompletedCOPDUnited Kingdom, Ireland
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Chiesi Farmaceutici S.p.A.RecruitingChronic Obstructive Pulmonary DiseaseBulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
-
Chiesi Farmaceutici S.p.A.RecruitingChronic Obstructive Pulmonary DiseaseBulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Chiesi Farmaceutici S.p.A.Completed
-
Chiesi Farmaceutici S.p.A.Quintiles, Inc.Completed
-
GlaxoSmithKlineCompletedAsthmaCanada, United States
-
Celon Pharma SANational Center for Research and Development, PolandCompletedMajor Depressive DisorderPoland
-
Chiesi Farmaceutici S.p.A.RecruitingUncontrolled AsthmaArgentina, Bulgaria, Czechia, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Poland, Romania, South Africa, Spain